MedTrace Logo

Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

NCT02407561 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2018-01-25

No results posted yet for this study

Summary

Patients with locally advanced rectal and esophageal carcinomas typically undergo neoadjuvant chemoradiation therapy prior to surgical resection. While response rates to this treatment differ among these three cancers, generally 20-25% of patients exhibit minimal or no response to preoperative chemoradiation therapy while 20-30% exhibit a complete pathologic response, and the remainder receiving a partial response.

This will be a multi-center study of patients with newly diagnosed rectal adenocarcinoma, or anal squamous cell carcinoma (SCC) who will undergo neoadjuvant chemoradiation prior to surgery. The tumor from these patients will be tested to determine whether response to neoadjuvant chemoradiation can be accurately predicted.

Conditions

  • Rectal Adenocarcinoma
  • Anal Adenocarcinoma
  • Anal Squamous Cell Carcinoma

Sponsors & Collaborators

  • Castle Biosciences Incorporated

    lead INDUSTRY

Principal Investigators

  • Robert Cook, PhD · Castle Biosciences Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02407561 on ClinicalTrials.gov